Search

News Complete remission of ALK-positive lung cancer in a patient after multiple lines of targeted therapy –⁠ a case study

Targeted treatment for driving oncogenic mutations has significantly improved outcomes for patients with ALK-positive non-small cell lung cancer (NSCLC) as well. A case study was recently published in the journal Frontiers in Oncology of a patient with advanced disease who achieved complete remission after several lines of therapy.

Source: Genetic Profile and Treatment of NSCLC 27. 12. 2021

Články časopisu Prevention of TEN in surgery, prolonged thromboprophylaxis

Author of the article: Z. Krška Source: Rozhledy v chirurgii | 5/2012 30. 5. 2012

News Pregabalin Relieves Patients with Central Neuropathic Pain

Treatment of central neuropathic pain, whether caused by spinal cord or cerebral damage, is often lengthy and not always successful. Study results show that pregabalin may be a suitable alternative to traditional preparations, affecting not only pain but also the quality of life of patients.

Source: Neuropathic Pain 25. 6. 2020

News Fexofenadine –⁠ Non-Sedative and Immunomodulatory Antihistamine in the Treatment of Allergic Symptoms

One of the biggest limitations of traditional antihistamines is the sedative effect on the central nervous system. Newer antihistamines do not cause sedation, are not associated with serious side effects, and some also have immunomodulatory effects.

Source: Viral infections 3. 3. 2022

News Pharmacokinetics of Concentrates for the Treatment of von Willebrand’s Disease

Von Willebrand's disease (vWD) is characterized by a deficiency or reduced functional capacity of von Willebrand factor (vWF) and, in more severe cases, by a deficiency of coagulation factor VIII (FVIII). Treatment usually requires repeated infusions of vWF and FVIII concentrate, with available products having different factor ratios. Repeated infusions of concentrates can lead to different FVIII exposures when using different products. The pharmacokinetics of two products with varying vWF and FVIII ratios have been compared in experimental preclinical and clinical studies.

Source: Von Willebrand Disease 14. 11. 2022

News Genuair®/Pressair® Inhaler in the Treatment of COPD –⁠ Minimum Errors During Inhalation and High Patient Satisfaction

The article by German authors summarizes the results achieved with the Genuair® inhaler (marketed in the USA under the name Pressair®), highlighting its ease of use, simple patient training, low error rates during inhalation compared to other inhalers, and high patient satisfaction and willingness to continue treatment.

Source: Treatment of Asthma and COPD 29. 3. 2021

News Can the Use of Statins Help Reduce the Risk of Dementia?

A meta-analysis published last year by Taiwanese experts evaluated the connection between the use of statins and the incidence of dementia. What conclusions did the authors reach?

Source: Cardiovascular Risks 23. 3. 2021

Články časopisu Nutrition in the acute phase of illness

Author of the article: František Novák Source: Vnitřní lékařství | 3/2019 4. 4. 2019

News Technology as an Aid in Home Oral Care

Good oral hygiene is a prerequisite for good health, both in the mouth area and in terms of overall condition. To make it more effective and easier, it is now possible to use technologically advanced tools that allow users to achieve and maintain high hygiene standards in regular daily care.

Source: Dental Care 22. 2. 2023

News The Importance of Limosilactobacillus reuteri in Administration to Diabetics with Gingivitis

We summarize the results of a clinical study on the effect of probiotics containing Limosilactobacillus reuteri on the improvement of gingivitis in patients with diabetes. It has been proven that the supplementary administration of L. reuteri statistically significantly improves gum health and helps to suppress gingival inflammation.

Source: GI, colic and microbiome 10. 11. 2022

News Reference Intervals of Prostate Health Index (PHI) in Healthy Men

For more specific prostate cancer screening, apart from prostate-specific antigen (PSA), its free fraction (fPSA) and one of its precursors, [-2]proPSA (p2PSA), are used today. From these parameters, the so-called Prostate Health Index (PHI) can be calculated. However, reference intervals for these parameters in a healthy population were not known until now.

Source: Prostate Health Index 2. 4. 2020

News Comprehensive View on Care for Patients with Urostomy

Thanks to improvements in surgical techniques and shorter hospital stays, patients with a stoma are returning to their home environment and to the care of outpatient doctors sooner. Quality care in the postoperative period is a crucial element in the prevention of complications, support of healing, and education of ostomy patients. Doctors caring for these patients should approach them comprehensively, considering all their needs and aspects.

Source: Ostomy 28. 2. 2020

News About Sartans: An Overview with Consideration of Their Position in the Current Coronavirus Situation

Sartans, or AT1 receptor blockers for angiotensin II (ARBs), are among the first-line antihypertensives, along with angiotensin-converting enzyme inhibitors (ACEi). These are well-tested drugs with a good safety profile. We offer a brief overview of the position of sartans in the current therapeutic strategy, including comments on their possible association with COVID-19, based on the state of knowledge as of early May 2020.

Source: Sartans in the Treatment of Hypertension 26. 5. 2020

News Previous Treatment of Osteoporosis May Affect the Efficacy of Romosozumab

A study conducted by a team of authors from several clinical sites in Japan shows that the type and duration of previous osteoporosis treatment just before starting romosozumab affects its therapeutic effect. Romosozumab, as an antibody targeting sclerostin, stimulates bone formation and suppresses bone resorption. The authors of the study investigated whether the efficacy of 12-month treatment with romosozumab depends on the duration of prior treatment with teriparatide, denosumab, or oral bisphosphonates.

Source: Osteoporosis – Trends in Sequential Therapy 9. 5. 2024

News Teriflunomide in the Treatment of RRMS: The Best Working Drug Is the One That the Patient Actually Takes

Teriflunomide is an oral disease-modifying drug (DMD) used in the therapy of relapsing-remitting multiple sclerosis (RRMS). The authors of the cited American study assessed adherence to this treatment and subsequently the effect of adherence on the occurrence of RRMS relapses and the utilization of healthcare services during the first year following the initial prescription of teriflunomide.

Source: Multiple Sclerosis 24. 4. 2023